Ignite Creation Date:
2025-12-24 @ 9:14 PM
Ignite Modification Date:
2025-12-30 @ 11:54 PM
Study NCT ID:
NCT05285904
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-01
First Post:
2022-03-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-05-12
Start Date Type:
ACTUAL
Primary Completion Date:
2026-03-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-03-31
Completion Date Type:
ESTIMATED
First Submit Date:
2022-03-08
First Submit QC Date:
None
Study First Post Date:
2022-03-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-27
Last Update Post Date:
2025-12-01
Last Update Post Date Type:
ESTIMATED